Developer docs
API playgroundTry for free, no card

Search company profiles

Hexagon Bio

Full company profile

uuid00007xm

Namestring
Hexagon Bio
Legal namestring
Hexagon Bio, Inc.
Websiteurl
hexagonbio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Hexagon Bio is a Menlo Park-based, privately held biopharmaceutical company founded in 2017 that applies a proprietary platform combining microbial genomics, machine learning, medicinal chemistry and synthetic biology to discover cytotoxic small molecules from fungal genomes for use as next-generation antibody-drug conjugate (ADC) payloads. The platform is anchored by an in-house database of more than 100,000 banked organismal strains and over 80,000 sequenced genomes — approximately 10x the size of all public databases combined — and has computationally mapped roughly 400 candidate ADC payload mechanisms of action spanning DNA/RNA, energy production, protein, lipid and cytoskeletal pathways. The company's lead program, HEX-360, is a HER2-targeting ADC built around a novel Protein Translation Inhibitor (PTI) payload designed to overcome resistance and tolerability limits of approved topoisomerase- and tubulin-based ADCs; HEX-360 is in IND-enabling studies with planned first-in-human entry in 1H 2027, supported by additional undisclosed programs (ADC 2, ADC 3 and Dual Combo 1) and a continuing novel-payload discovery track. Leadership includes CEO and co-founder Maureen Hillenmeyer, CSO Tara Arvedson and SVP Drug Discovery Victor Cee — both former Amgen leaders of the LUMAKRAS (sotorasib) program — under Chairman David Goeddel (Managing Partner, The Column Group).

Hexagon is pre-revenue with no marketed products; its economic model is built on three future revenue streams: (1) pharmaceutical development and licensing of ADC candidates through partnerships with larger biopharma, (2) royalty participation on commercialized assets, and (3) research funding, milestones and royalties from the December 2025 multi-million dollar joint venture with Corteva Agriscience to develop nature-inspired crop protection solutions. The company is financed by approximately $185.3 million of cumulative venture capital across the Column Group, 8VC, Two Sigma Ventures, Nextech Invest, SoftBank Vision Fund 2, Casdin Capital and CPP Investments, and reaches the market primarily through scientific publications, conference presentations (AACR, WADC, ADC Analytical Development Summit), enterprise partnership outreach and a professional website; downstream ADC distribution is expected to flow through pharmaceutical licensing deals. Customer segments span oncology solid-tumor patients (primary), hematologic malignancies, infectious-disease applications and, via the Corteva partnership, agricultural crop protection.

Short descriptiontext

Hexagon Bio is a privately held, Menlo Park-based biopharmaceutical company using genomics, machine learning and synthetic biology to discover novel cytotoxic small molecules from microbial genomes for use as next-generation ADC payloads, with lead HER2 program HEX-360 in IND-enabling studies and a 2025 joint venture with Corteva for crop protection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, ADC payloads, natural product discovery, oncology therapeutics, genomics drug discovery
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals (ADC Development)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Development and Licensing
TypeLicensing Royalties
Description

Hexagon Bio is a pre-revenue biopharmaceutical company developing a pipeline of next-generation ADC candidates. Revenue will be generated through clinical development partnerships, licensing deals, and eventual product commercialization upon regulatory approval.

hexagonbio.com
2Agricultural Technology Partnership
TypeLicensing Royalties
Description

Multi-million dollar joint venture with Corteva Agriscience for nature-inspired crop protection solutions using fungal compounds, representing potential revenue through research funding, milestone payments, and future product royalties in agricultural applications.

businessrecord.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Hexagon Bio is a biopharmaceutical company that discovers and develops novel small-molecule payloads for antibody-drug conjugates (ADCs) to overcome resistance to existing cancer treatments. The company's pipeline includes HER2-targeting ADC (HEX-360) and other solid tumor programs built on a proprietary platform combining genomics, machine learning, metabolomics, and synthetic biology to mine cytotoxic natural products from microbial genomes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Potency demonstrated at ≤10 nM concentrations in >90% of nearly 200 cell lines tested including topoisomerase and tubulin inhibitor-resistant lines
+3 more records
Product overview1 text field

Hexagon Bio is a biopharmaceutical company pioneering the discovery of novel small molecule payloads for antibody-drug conjugates (ADCs). The company's flagship offering is its proprietary ADC Payload Discovery Engine—a platform combining genomics, machine learning, metabolomics, chemistry, and synthetic biology to mine cytotoxic natural products from microbial genomes for use as ADC payloads. The product portfolio includes lead program HEX-360 (HER2-targeting ADC with novel Protein Translation Inhibitor payload in IND-enabling studies, planned clinical entry 1H 2027), ADC 2 (undisclosed solid tumor target), ADC 3 (dual-payload strategy), and Dual Combo 1. The platform has identified approximately 400 potential ADC payload mechanisms of action spanning cell cycle, transcription, translation, cytoskeleton, and other cancer-related pathways. Beyond oncology, the company expanded into agriculture through a December 2025 joint venture with Corteva for nature-inspired crop protection solutions.

Product and service4 records
1HEX-360
CategoryOncology Biopharmaceuticals
Description

HER2-targeting antibody-drug conjugate (ADC) featuring a novel Protein Translation Inhibitor (PTI) payload discovered by Hexagon Bio, designed to overcome resistance and poor tolerability associated with existing payload classes, targeting solid tumors with planned clinical entry in 1H 2027.

2ADC 2
CategoryOncology Biopharmaceuticals
Description

Undisclosed next-generation ADC program targeting solid tumors, leveraging novel payload mechanisms beyond topoisomerase and tubulin inhibitors.

3ADC 3
CategoryOncology Biopharmaceuticals
Description

Dual-payload ADC program utilizing multiple novel payload mechanisms to address resistance to existing ADC treatments and expand indication space.

4Dual Combo 1
CategoryOncology Biopharmaceuticals
Description

Combination strategy involving dual payloads for enhanced therapeutic efficacy and overcoming resistance mechanisms in cancer treatment.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Corteva Agriscience
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Corteva and Hexagon Bio formed a multi-million dollar joint venture on December 16, 2025, to accelerate the development of next-generation crop protection solutions inspired by nature. The partnership integrates Corteva's nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio's AI and synthetic biology-powered natural-product discovery platform. This marks the first ag-pharma collaboration for both companies. The JV was formed through Corteva Catalyst, Corteva's investment and collaboration platform that has partnered with 11 companies since its March 2024 launch. Commercial products remain years away given typical regulatory timelines.

finance.yahoo.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage developer of next-generation ADCs with novel payload platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Closely comparable to Hexagon in mission and modality.

TypeDirect peer
Description

Developer of antibody-drug conjugates with novel payloads and tumor-targeting approaches for solid tumors. Comparable pipeline stage and ADC-focused strategy.

TypeDirect peer
Description

German biotech developing novel ADC payloads and linkers with proprietary chemistry platforms. Directly comparable as a novel-payload ADC developer focused on solid tumors.

TypeDirect peer
Description

Clinical-stage developer of immune-stimulating antibody conjugates (ISACs), a related next-generation ADC approach. Comparable mechanism novelty and oncology focus.

TypeDirect peer
Description

Developer of Probody-based conditionally activated ADCs and other next-generation antibody conjugates. Comparable platform-based ADC strategy with novel payload approaches.

TypeDirect peer
Description

Developer of ADCs and other biologics using cell-free protein synthesis platform with multiple novel payload programs in oncology. Comparable ADC pipeline strategy.

TypeBroad incumbent
Description

Major pharmaceutical company behind Enhertu, the leading HER2-targeting ADC. Represents the dominant incumbent that HEX-360 directly competes against in HER2-positive tumors.

TypeBroad incumbent
Description

Pfizer's Seagen subsidiary pioneered ADC commercialization with Adcetris and other approved ADCs. Represents the broad incumbent ADC platform competitor Hexagon must differentiate against.

TypeEmerging player
Description

AI-driven drug discovery platform combining machine learning with high-throughput biology to discover novel therapeutics. Comparable platform-approach to small molecule discovery at Hexagon, though with broader therapeutic scope.

TypeEmerging player
Description

Precision oncology company developing targeted therapies including synthetic lethality and ADC-adjacent programs. Connected to Hexagon via board director Yujiro Hata (IDEAYA CEO).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hexagon Bio

Oncology Biopharmaceuticals (ADC Development)hexagonbio.com

Hexagon Bio is a privately held, Menlo Park-based biopharmaceutical company using genomics, machine learning and synthetic biology to discover novel cytotoxic small molecules from microbial genomes for use as next-generation ADC payloads, with lead HER2 program HEX-360 in IND-enabling studies and a 2025 joint venture with Corteva for crop protection.

What Hexagon Bio does

Hexagon Bio is a Menlo Park-based, privately held biopharmaceutical company founded in 2017 that applies a proprietary platform combining microbial genomics, machine learning, medicinal chemistry and synthetic biology to discover cytotoxic small molecules from fungal genomes for use as next-generation antibody-drug conjugate (ADC) payloads. The platform is anchored by an in-house database of more than 100,000 banked organismal strains and over 80,000 sequenced genomes — approximately 10x the size of all public databases combined — and has computationally mapped roughly 400 candidate ADC payload mechanisms of action spanning DNA/RNA, energy production, protein, lipid and cytoskeletal pathways. The company's lead program, HEX-360, is a HER2-targeting ADC built around a novel Protein Translation Inhibitor (PTI) payload designed to overcome resistance and tolerability limits of approved topoisomerase- and tubulin-based ADCs; HEX-360 is in IND-enabling studies with planned first-in-human entry in 1H 2027, supported by additional undisclosed programs (ADC 2, ADC 3 and Dual Combo 1) and a continuing novel-payload discovery track. Leadership includes CEO and co-founder Maureen Hillenmeyer, CSO Tara Arvedson and SVP Drug Discovery Victor Cee — both former Amgen leaders of the LUMAKRAS (sotorasib) program — under Chairman David Goeddel (Managing Partner, The Column Group).

Hexagon is pre-revenue with no marketed products; its economic model is built on three future revenue streams: (1) pharmaceutical development and licensing of ADC candidates through partnerships with larger biopharma, (2) royalty participation on commercialized assets, and (3) research funding, milestones and royalties from the December 2025 multi-million dollar joint venture with Corteva Agriscience to develop nature-inspired crop protection solutions. The company is financed by approximately $185.3 million of cumulative venture capital across the Column Group, 8VC, Two Sigma Ventures, Nextech Invest, SoftBank Vision Fund 2, Casdin Capital and CPP Investments, and reaches the market primarily through scientific publications, conference presentations (AACR, WADC, ADC Analytical Development Summit), enterprise partnership outreach and a professional website; downstream ADC distribution is expected to flow through pharmaceutical licensing deals. Customer segments span oncology solid-tumor patients (primary), hematologic malignancies, infectious-disease applications and, via the Corteva partnership, agricultural crop protection.

Hexagon Bio firmographics

Firmographics
Name
Hexagon Bio
Legal name
Hexagon Bio, Inc.
Website
https://hexagonbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Hexagon Bio is a privately held, Menlo Park-based biopharmaceutical company using genomics, machine learning and synthetic biology to discover novel cytotoxic small molecules from microbial genomes for use as next-generation ADC payloads, with lead HER2 program HEX-360 in IND-enabling studies and a 2025 joint venture with Corteva for crop protection.
Ownership category
akta.pro rank

Hexagon Bio industry classification

Industry
Product category
Oncology Biopharmaceuticals (ADC Development)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • ADC payloads
  • Natural product discovery
  • Oncology therapeutics
  • Genomics drug discovery

Where Hexagon Bio is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hexagon Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Development and Licensing: Hexagon Bio is a pre-revenue biopharmaceutical company developing a pipeline of next-generation ADC candidates. Revenue will be generated through clinical development partnerships, licensing deals, and eventual product commercialization upon regulatory approval.
  2. Agricultural Technology Partnership: Multi-million dollar joint venture with Corteva Agriscience for nature-inspired crop protection solutions using fungal compounds, representing potential revenue through research funding, milestone payments, and future product royalties in agricultural applications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Hexagon Bio product offering

Product offering

Core offering

Hexagon Bio is a biopharmaceutical company that discovers and develops novel small-molecule payloads for antibody-drug conjugates (ADCs) to overcome resistance to existing cancer treatments. The company's pipeline includes HER2-targeting ADC (HEX-360) and other solid tumor programs built on a proprietary platform combining genomics, machine learning, metabolomics, and synthetic biology to mine cytotoxic natural products from microbial genomes.

Product overview

Hexagon Bio is a biopharmaceutical company pioneering the discovery of novel small molecule payloads for antibody-drug conjugates (ADCs). The company's flagship offering is its proprietary ADC Payload Discovery Engine—a platform combining genomics, machine learning, metabolomics, chemistry, and synthetic biology to mine cytotoxic natural products from microbial genomes for use as ADC payloads. The product portfolio includes lead program HEX-360 (HER2-targeting ADC with novel Protein Translation Inhibitor payload in IND-enabling studies, planned clinical entry 1H 2027), ADC 2 (undisclosed solid tumor target), ADC 3 (dual-payload strategy), and Dual Combo 1. The platform has identified approximately 400 potential ADC payload mechanisms of action spanning cell cycle, transcription, translation, cytoskeleton, and other cancer-related pathways. Beyond oncology, the company expanded into agriculture through a December 2025 joint venture with Corteva for nature-inspired crop protection solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • HEX-360 HER2-targeting antibody-drug conjugate (ADC) featuring a novel Protein Translation Inhibitor (PTI) payload discovered by Hexagon Bio, designed to overcome resistance and poor tolerability associated with existing payload classes, targeting solid tumors with planned clinical entry in 1H 2027.
  • ADC 2 Undisclosed next-generation ADC program targeting solid tumors, leveraging novel payload mechanisms beyond topoisomerase and tubulin inhibitors.
  • ADC 3 Dual-payload ADC program utilizing multiple novel payload mechanisms to address resistance to existing ADC treatments and expand indication space.
  • Dual Combo 1 Combination strategy involving dual payloads for enhanced therapeutic efficacy and overcoming resistance mechanisms in cancer treatment.

Quantifiable outcome

  • Potency demonstrated at ≤10 nM concentrations in >90% of nearly 200 cell lines tested including topoisomerase and tubulin inhibitor-resistant lines
  • +3 more outcomes

Companies that use Hexagon Bio

Customer profile

Segments4 records

Ideal customer profiles2 records

Hexagon Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Hexagon Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Corteva AgriscienceflagshipStrategic or Co-development Partner · 16 December 2025Corteva and Hexagon Bio formed a multi-million dollar joint venture on December 16, 2025, to accelerate the development of next-generation crop protection solutions inspired by nature. The partnership integrates Corteva's nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio's AI and synthetic biology-powered natural-product discovery platform. This marks the first ag-pharma collaboration for both companies. The JV was formed through Corteva Catalyst, Corteva's investment and collaboration platform that has partnered with 11 companies since its March 2024 launch. Commercial products remain years away given typical regulatory timelines.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Hexagon Bio competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage developer of next-generation ADCs with novel payload platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Closely comparable to Hexagon in mission and modality.
  • Pyxis Oncology: Developer of antibody-drug conjugates with novel payloads and tumor-targeting approaches for solid tumors. Comparable pipeline stage and ADC-focused strategy.
  • Tubulis: German biotech developing novel ADC payloads and linkers with proprietary chemistry platforms. Directly comparable as a novel-payload ADC developer focused on solid tumors.
  • Bolt Biotherapeutics: Clinical-stage developer of immune-stimulating antibody conjugates (ISACs), a related next-generation ADC approach. Comparable mechanism novelty and oncology focus.
  • CytomX Therapeutics: Developer of Probody-based conditionally activated ADCs and other next-generation antibody conjugates. Comparable platform-based ADC strategy with novel payload approaches.
  • Sutro Biopharma: Developer of ADCs and other biologics using cell-free protein synthesis platform with multiple novel payload programs in oncology. Comparable ADC pipeline strategy.

Broad incumbents

  • Daiichi Sankyo: Major pharmaceutical company behind Enhertu, the leading HER2-targeting ADC. Represents the dominant incumbent that HEX-360 directly competes against in HER2-positive tumors.
  • Pfizer (Seagen): Pfizer's Seagen subsidiary pioneered ADC commercialization with Adcetris and other approved ADCs. Represents the broad incumbent ADC platform competitor Hexagon must differentiate against.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining machine learning with high-throughput biology to discover novel therapeutics. Comparable platform-approach to small molecule discovery at Hexagon, though with broader therapeutic scope.
  • IDEAYA Biosciences: Precision oncology company developing targeted therapies including synthetic lethality and ADC-adjacent programs. Connected to Hexagon via board director Yujiro Hata (IDEAYA CEO).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Hexagon Bio social profiles

Digital presence

Hexagon Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hexagon Bio leadership team

Management profile

Number of profiles

Profiles11 records

Hexagon Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hexagon Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hexagon Bio

What does Hexagon Bio do?

Hexagon Bio is a biopharmaceutical company that discovers and develops novel small-molecule payloads for antibody-drug conjugates (ADCs) to overcome resistance to existing cancer treatments. The company's pipeline includes HER2-targeting ADC (HEX-360) and other solid tumor programs built on a proprietary platform combining genomics, machine learning, metabolomics, and synthetic biology to mine cytotoxic natural products from microbial genomes.

Is Hexagon Bio a public or private company?

Hexagon Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hexagon Bio founded?

Hexagon Bio was founded in 2017. It employs 51 to 100 people.

Where is Hexagon Bio based?

Hexagon Bio is headquartered in Menlo Park, United States, in the North America region.

How does Hexagon Bio make money?

Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are agricultural Technology Partnership.

Who are Hexagon Bio's main competitors?

Direct peers on record are Mersana Therapeutics, Pyxis Oncology, Tubulis, Bolt Biotherapeutics, CytomX Therapeutics and Sutro Biopharma. Broad incumbents are Daiichi Sankyo and Pfizer (Seagen). Emerging players are Recursion Pharmaceuticals and IDEAYA Biosciences.

Does Hexagon Bio have an API?

No public API is recorded for Hexagon Bio.

What industry is Hexagon Bio in?

Hexagon Bio's product category is Oncology Biopharmaceuticals (ADC Development). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsHexagon Bio Raises $62M in Series C FundingHexagon Bio raised $62M in Series C funding led by The Column Group, with participation from Nextech Invest, Deviation Capital, 8VC, and CPP Investments. The company will use the funds to support the Phase 1 clinical trial of HEX-360 and advance additional payload mechanisms from its proprietary platform.citybizHexagon Bio Raises $62M to Advance Experimental Cancer DrugHexagon Bio raised $62 million in Series C financing led by The Column Group to advance its experimental cancer drug HEX-360. The company's lead program targets HER2 and showed efficacy comparable to or greater than Enhertu in preclinical models. The funding will support clinical testing and discovery of new antibody-drug conjugate payloads.Startup ResearcherHexagon Bio Closes $62 Million Series C Funding RoundHexagon Bio closed a $62 million Series C round led by The Column Group on October 23, 2026. Proceeds will fund the Phase 1 trial of HEX-360, a HER2-targeting ADC with a novel translation inhibitor payload, anticipated to begin in the first half of 2027. The company aims to advance its pipeline of next-generation antibody-drug conjugates.VC News DailyHexagon Bio Lands $62 Million Series CHexagon Bio closed a $62 million Series C financing led by The Column Group, with participation from existing investors including Nextech Invest, Deviation Capital, 8VC, and CPP Investments. The biopharmaceutical company focuses on novel payload mechanisms for antibody-drug conjugates.Business & FinancialHexagon Bio Raises $62 Million Series C Financing To Advance HEX-360 Into The Clinic And Expand Pipeline Of Antibody-Drug Conjugates With Novel Payload MechanismsHexagon Bio closed a $62 million Series C led by The Column Group to advance HEX-360, a HER2-targeting ADC with a novel translation inhibitor payload. The company plans to initiate a Phase 1 trial in the first half of 2027 and expand its pipeline of novel payload mechanisms.BitlyHexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload MechanismsHexagon Bio closed a $62 million Series C led by The Column Group to advance HEX-360, a HER2-targeting ADC with a novel translation inhibitor payload. The company anticipates initiating a Phase 1 trial in the first half of 2027 and will use proceeds to discover orthogonal payload mechanisms.GlobeNewswireHexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload MechanismsHexagon Bio closed a $62 million Series C led by The Column Group. Proceeds will fund the Phase 1 trial of HEX-360, a HER2-targeting ADC with a novel translation inhibitor payload, anticipated to begin in the first half of 2027. The company will also advance its proprietary ADC platform to discover orthogonal payload mechanisms.GlobeNewswireHexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADCHexagon Bio announced a clinical advisory board of breast cancer experts to guide its lead ADC candidate HEX-360. The company plans to initiate first-in-human studies in the first half of 2027. HEX-360 features a novel translation inhibitor payload designed to overcome resistance and improve tolerability.Investing.comCorteva earnings on deck as corn acres debate takes center stage By Investing.comCorteva is scheduled to report fourth-quarter earnings Tuesday after market close, with analysts forecasting 22 cents EPS on $4.24 billion in revenue—a sharp improvement from the Q3 loss of 23 cents per share. Investors are closely watching the company's 2026 outlook, particularly U.S. corn planted acres, which analysts say are key to the earnings dynamic as industry forecasts project acreage could decline to 95 million acres from the 98.8 million planted in 2025. The company has recently launched a 50:50 biofuel joint venture with bp and announced a partnership with Hexagon Bio for nature-inspired crop protection solutions.Investing.comCorteva earnings on deck as corn acres debate takes center stage By Investing.comCorteva is set to report fourth-quarter earnings with analysts expecting 22 cents EPS on $4.24 billion revenue, a sharp turnaround from the prior quarter's 23-cent loss. The key investor focus is on the company's 2026 guidance amid debate over expected U.S. corn planted acres, which industry forecasts project could decline to 95 million acres from 98.8 million in 2025. The article notes recent strategic initiatives including a January joint venture with bp for biofuel feedstock and a December partnership with Hexagon Bio for crop protection solutions.